• 1
    WHO. Draft WHO guidelines on the use of vaccines and antivirals during influenza pandemics. Wkly Epidemiol Rec 2002;77: 394404.
  • 2
    Yewdell J, Garcia-Sastre A. Influenza virus still surprises. Curr Opin Microbiol 2002;5: 41418.
  • 3
    Reid AH, Janczewski TA, Lourens RM. et al. 1918 influenza pandemic caused by highly conserved viruses with two receptor-binding variants. Emerg Infect Dis 2003;9: 124953.
  • 4
    Reid AH, Taubenberger JK, Fanning TG. The 1918 Spanish influenza: integrating history and biology. Microbes Infect 2001;3: 817.
  • 5
    Barry DW, Mayner RE, Staton E. et al. Comparative trial of influenza vaccines. I. Immunogenicity of whole virus and split product vaccines in man. Am J Epidemiol 1976;104: 3446.
  • 6
    Gross PA, Ennis FA, Gaerlan PF, Denson LJ, Denning CR, Schiffman D. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 1977;136: 62332.
  • 7
    Wood JM. Developing vaccines against pandemic influenza. Philos Trans R Soc Lond B Biol Sci 2001;356: 195360.
  • 8
    Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357: 193743.
  • 9
    Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004;4: 499509.
  • 10
    Cox RJ, Mykkeltvedt E, Robertson J, Haaheim LR. Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication. Scand J Immunol 2002;55: 1423.
  • 11
    Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994;12: 99399.
  • 12
    Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 1995;171: 198203.
  • 13
    Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938;27: 49397.
  • 14
    Hasbold J, Corcoran LM, Tarlinton DM, Tangye SG, Hodgkin PD. Evidence from the generation of immunoglobulin G-secreting cells that stochastic mechanisms regulate lymphocyte differentiation. Nat Immunol 2004;5: 5563.
  • 15
    O'Connor BP, Gleeson MW, Noelle RJ, Erickson LD. The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev 2003;194: 6176.
  • 16
    Cyster JG. Homing of antibody secreting cells. Immunol Rev 2003;194: 4860.
  • 17
    Kendal AP, Pereira MS, Skehel J. Concepts and procedures for laboratory-based influenza surveillance. Publication No. B17-35. Centers for Disease Control, Atlanta, GA, 1982.
  • 18
    Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70: 76777.
  • 19
    Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines. CPMP/BWP/214/96, Circular No. 96-0666: 1-22, 1997.
  • 20
    Boyer KM, Cherry JD, Welliver RC et al. IgM, IgG antibody responses after immunization of children with inactivated monovalent (A/New Jersey/76) and bivalent (A/New Jersey/76-A/Victoria/75) influenza virus vaccines. J Infect Dis 1977;136 (Suppl. ):S66571.
  • 21
    Stephenson I, Nicholson KG, Colegate A et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21: 168793.
  • 22
    Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol (Berl) 2002;191: 2038.
  • 23
    Moran TM, Park H, Fernandez-Sesma A, Schulman JL. Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 1999;180: 57985.
  • 24
    Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004;103: 16371.
  • 25
    Charoenvit Y, Goel N, Whelan M, Rosenthal KS, Zimmerman DH. CEL-1000-a peptide with adjuvant activity for Th1 immune responses. Vaccine 2004;22: 236873.
  • 26
    Chattergoon MA, Saulino V, Shames JP, Stein J, Montaner LJ, Weiner DB. Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine 2004;22: 174450.
  • 27
    Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003;21: 321218.
  • 28
    Armerding D, Rossiter H, Ghazzouli I, Liehl E. Evaluation of live and inactivated influenza A virus vaccines in a mouse model. J Infect Dis 1982;145: 32030.
  • 29
    Nguyen HH, Van Ginkel FW, Vu HL, McGhee JR, Mestecky J. Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 2001;183: 36876.
  • 30
    Stevens TL, Bossie A, Sanders VM et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988;334: 25558.
  • 31
    Markine-Goriaynoff D, Van Der Logt JT, Truyens C et al. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int Immunol 2000;12: 22330.
  • 32
    Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 2004;57: 23647.
  • 33
    Peltoniemi J, Setala N, Broberg E. et al. Semliki Forest virus infection is enhanced in Th1-prone SJL mice but not in Th2-prone BALB/c mice during Linomide-induced immunomodulation. J Neuroimmunol 2002;132: 8392.
  • 34
    Guinazu N, Pellegrini A, Giordanengo L. et al. Immune response to a major Trypanosoma cruzi antigen, cruzipain, is differentially modulated in C57BL/6 and BALB/c mice. Microbes Infect 2004;6: 125058.
  • 35
    Ramakrishna C, Ravi V, Desai A, Subbakrishna DK, Shankar SK, Chandramuki A. T helper responses to Japanese encephalitis virus infection are dependent on the route of inoculation and the strain of mouse used. J Gen Virol 2003;84: 155967.
  • 36
    Liang S, Mozdzanowska K, Palladino G, Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 1994;152: 165361.
  • 37
    Fazekas G, Rosenwirth B, Dukor P, Gergely J, Rajnavolgyi E. IgG isotype distribution of local and systemic immune responses induced by influenza virus infection. Eur J Immunol 1994;24: 306367.
  • 38
    Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001;166: 738188.
  • 39
    Arkema A, Huckriede A, Schoen P, Wilschut J, Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine 2000;18: 132733.
  • 40
    Bungener L, Serre K, Bijl L et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002;20: 228795.
  • 41
    Schumacher R, Adamina M, Zurbriggen R. et al. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 2004;22: 71423.
  • 42
    Sambhara S, Kurichh A, Miranda R et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 2001;211: 14353.
  • 43
    Speidel K, Osen W, Faath S et al. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol 1997;27: 239199.
  • 44
    Saurwein-Teissl M, Zisterer K, Schmitt TL, Gluck R, Cryz S, Grubeck-Loebenstein B. Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation. Clin Exp Immunol 1998;114: 27176.